MARION ELIZABETH SCOGGINS
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ultrasonography, Mammary | 8 | 2022 | 380 | 2.190 |
Why?
|
| Mammography | 11 | 2023 | 1010 | 1.570 |
Why?
|
| Breast Neoplasms | 19 | 2023 | 15694 | 0.860 |
Why?
|
| Breast | 5 | 2022 | 1344 | 0.770 |
Why?
|
| Triple Negative Breast Neoplasms | 8 | 2023 | 1215 | 0.760 |
Why?
|
| Accreditation | 1 | 2020 | 126 | 0.710 |
Why?
|
| Fiducial Markers | 1 | 2019 | 96 | 0.680 |
Why?
|
| Carcinoma, Ductal, Breast | 4 | 2020 | 1216 | 0.620 |
Why?
|
| Preoperative Care | 3 | 2022 | 1529 | 0.610 |
Why?
|
| Guideline Adherence | 1 | 2020 | 636 | 0.540 |
Why?
|
| Radiology | 1 | 2020 | 434 | 0.500 |
Why?
|
| Societies, Medical | 1 | 2020 | 1335 | 0.470 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2023 | 7702 | 0.420 |
Why?
|
| Carcinoma in Situ | 1 | 2015 | 487 | 0.400 |
Why?
|
| Neoadjuvant Therapy | 10 | 2023 | 4975 | 0.390 |
Why?
|
| Calcinosis | 3 | 2021 | 423 | 0.350 |
Why?
|
| Carcinoma, Lobular | 1 | 2013 | 611 | 0.340 |
Why?
|
| Iodine Radioisotopes | 2 | 2022 | 371 | 0.340 |
Why?
|
| Early Detection of Cancer | 3 | 2021 | 1258 | 0.220 |
Why?
|
| Phthalazines | 2 | 2022 | 253 | 0.200 |
Why?
|
| Female | 24 | 2023 | 141928 | 0.200 |
Why?
|
| Mastectomy, Segmental | 3 | 2022 | 1026 | 0.190 |
Why?
|
| Paget's Disease, Mammary | 1 | 2020 | 41 | 0.190 |
Why?
|
| Radar | 1 | 2019 | 2 | 0.180 |
Why?
|
| Radio Frequency Identification Device | 1 | 2019 | 4 | 0.180 |
Why?
|
| Stainless Steel | 1 | 2019 | 26 | 0.180 |
Why?
|
| Breast Implantation | 1 | 2023 | 228 | 0.180 |
Why?
|
| Drug Implants | 1 | 2019 | 46 | 0.180 |
Why?
|
| Magnets | 1 | 2019 | 32 | 0.180 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2015 | 674 | 0.180 |
Why?
|
| Breast Neoplasms, Male | 1 | 2020 | 229 | 0.170 |
Why?
|
| Needles | 1 | 2019 | 107 | 0.170 |
Why?
|
| Foreign-Body Migration | 1 | 2019 | 117 | 0.170 |
Why?
|
| Gamma Rays | 1 | 2019 | 242 | 0.160 |
Why?
|
| Breast Implants | 1 | 2023 | 391 | 0.160 |
Why?
|
| Humans | 27 | 2023 | 261506 | 0.150 |
Why?
|
| Middle Aged | 12 | 2021 | 86204 | 0.140 |
Why?
|
| Multimodal Imaging | 2 | 2022 | 550 | 0.140 |
Why?
|
| Angiomatosis | 1 | 2016 | 26 | 0.140 |
Why?
|
| Mammaplasty | 1 | 2023 | 780 | 0.130 |
Why?
|
| Clinical Protocols | 1 | 2017 | 467 | 0.130 |
Why?
|
| Patient Compliance | 1 | 2019 | 667 | 0.130 |
Why?
|
| Hyperplasia | 1 | 2016 | 557 | 0.120 |
Why?
|
| Breast Diseases | 1 | 2016 | 201 | 0.120 |
Why?
|
| Radiometry | 1 | 2019 | 980 | 0.120 |
Why?
|
| Image Enhancement | 1 | 2017 | 561 | 0.120 |
Why?
|
| Mass Screening | 1 | 2022 | 1509 | 0.110 |
Why?
|
| Magnetic Phenomena | 2 | 2022 | 26 | 0.100 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 4971 | 0.100 |
Why?
|
| Aged | 7 | 2023 | 70117 | 0.100 |
Why?
|
| Adult | 7 | 2021 | 77950 | 0.100 |
Why?
|
| Neoplasm Grading | 1 | 2015 | 1742 | 0.090 |
Why?
|
| Prospective Studies | 5 | 2023 | 12873 | 0.090 |
Why?
|
| Biopsy, Needle | 1 | 2013 | 1363 | 0.080 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2022 | 341 | 0.080 |
Why?
|
| Retrospective Studies | 8 | 2023 | 37905 | 0.080 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 29902 | 0.070 |
Why?
|
| United States | 2 | 2023 | 15433 | 0.070 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 2 | 2022 | 992 | 0.070 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 2 | 2022 | 479 | 0.070 |
Why?
|
| Neoplasm Staging | 3 | 2021 | 13658 | 0.070 |
Why?
|
| Mastectomy | 3 | 2022 | 1534 | 0.070 |
Why?
|
| Receptors, Estrogen | 1 | 2013 | 2086 | 0.070 |
Why?
|
| Germ-Line Mutation | 2 | 2022 | 1046 | 0.070 |
Why?
|
| Time Factors | 1 | 2019 | 12926 | 0.070 |
Why?
|
| Contrast Media | 2 | 2022 | 1472 | 0.060 |
Why?
|
| Ultrasonography | 2 | 2021 | 1863 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2022 | 2803 | 0.060 |
Why?
|
| Rupture | 1 | 2023 | 61 | 0.060 |
Why?
|
| Silicone Gels | 1 | 2023 | 28 | 0.060 |
Why?
|
| United States Food and Drug Administration | 1 | 2023 | 332 | 0.050 |
Why?
|
| Staining and Labeling | 1 | 2022 | 429 | 0.050 |
Why?
|
| Surgical Instruments | 1 | 2021 | 138 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2022 | 285 | 0.050 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2022 | 1062 | 0.050 |
Why?
|
| Anthracyclines | 1 | 2021 | 331 | 0.040 |
Why?
|
| Necrosis | 1 | 2020 | 580 | 0.040 |
Why?
|
| Axilla | 1 | 2021 | 902 | 0.040 |
Why?
|
| Taxoids | 1 | 2021 | 967 | 0.040 |
Why?
|
| BRCA2 Protein | 1 | 2019 | 358 | 0.040 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2015 | 10035 | 0.040 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 493 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2023 | 32848 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2022 | 1048 | 0.030 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 1022 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 1544 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2021 | 1987 | 0.030 |
Why?
|
| Biopsy | 1 | 2022 | 3443 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2019 | 492 | 0.030 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2021 | 1415 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 14889 | 0.030 |
Why?
|
| Registries | 1 | 2021 | 2170 | 0.030 |
Why?
|
| Lymph Node Excision | 1 | 2021 | 1959 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2021 | 4892 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2020 | 3981 | 0.030 |
Why?
|
| Genomics | 1 | 2023 | 2738 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2017 | 2292 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 2864 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 3890 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 4844 | 0.020 |
Why?
|
| Prognosis | 2 | 2021 | 21713 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2021 | 2967 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2017 | 6009 | 0.020 |
Why?
|
| Incidence | 1 | 2015 | 5673 | 0.020 |
Why?
|
| Biomarkers, Tumor | 1 | 2023 | 10331 | 0.020 |
Why?
|
| Young Adult | 1 | 2021 | 21445 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2021 | 15862 | 0.010 |
Why?
|
| Risk Factors | 1 | 2015 | 17523 | 0.010 |
Why?
|
| Male | 1 | 2020 | 123000 | 0.010 |
Why?
|